Immunological Phenotype of Desmoid-fibromatosis-affected Patients.

This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic therapy. The study includes analysis of the tumor immune microenvironment (TIME), circulating immune and inflammatory molecules, immune cell subsets, and circulating tumor DNA (ctDNA). The goal is to identify biomarkers associated with spontaneous or treatment-induced tumor regression and to evaluate potential correlations with specific ß-catenin mutations.

NCT Number	NCT07496242
Lead Sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Collaborators: Campus Bio-Medico University, Candiolo Cancer Institute - IRCCS, Azienda Ospedaliero-Universitaria Careggi, Azienda USL Toscana Centro, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo, Erasmus University Rotterdam, Istituto Oncologico Veneto IRCCS
Conditions	Desmoid-Type Fibromatosis
Enrollment	200 participants
Start Date	2025-05-27
Primary Completion	2026-08-31 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-27